Xenon Pharmaceuticals Inc. | Business Contracts

Employment Agreement, dated November 7, 2022, by and between the Company and Andrea DiFabio (Filed With SEC on November 8, 2022)

Consent to Alterations and Lease Modification Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective May 19, 2022 (Filed With SEC on August 9, 2022)

Form of Pre-Funded Warrant (Filed With SEC on June 23, 2022)

Amendment No. 1 to the At-the-Market Equity Offering Sales Agreement, dated March 1, 2022, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company,... (Filed With SEC on March 1, 2022)

Description of Securities (Filed With SEC on March 9, 2020)

Underwriting Agreement, dated June 22, 2022, among Xenon Pharmaceuticals Inc., Jefferies LLC, J.P. Morgan Securities LLC, SVB Securities LLC and Stifel, Nicolaus & Company,... (Filed With SEC on June 23, 2022)

Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder (Filed With SEC on June 2, 2022)

Amendment #2, dated February 25, 2022, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc (Filed With SEC on March 1, 2022)

Share Purchase Agreement, dated as of January 11, 2022, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc (Filed With SEC on January 12, 2022)

Lease Agreement, dated as of November 24, 2021, by and between the Company and Redstone Enterprises Ltd (Filed With SEC on December 1, 2021)

Employment Agreement, dated August 18, 2021, by and between the Company and Christopher Kenney (Filed With SEC on November 10, 2021)

Form of Pre-Funded Warrant (Filed With SEC on October 6, 2021)

Underwriting Agreement, dated October 5, 2021, among Xenon Pharmaceuticals Inc., Jefferies LLC, SVB Leerink LLC, and Stifel, Nicolaus & Company, Incorporated, as representatives... (Filed With SEC on October 6, 2021)

Share Purchase Agreement, dated as of September 8, 2021, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc (Filed With SEC on September 8, 2021)

Termination Agreement, dated August 6, 2021, by and among Xenon Pharmaceuticals Inc., Genentech, Inc. and F. Hoffmann-La Roche Ltd (Filed With SEC on August 11, 2021)

Form of Pre-Funded Warrant (Filed With SEC on March 10, 2021)

Underwriting Agreement, dated March 9, 2021, among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several... (Filed With SEC on March 10, 2021)

Lease Modification Agreement, effective October 5, 2020, by and between the Company and Redstone Enterprises Ltd (Filed With SEC on March 1, 2021)

Form of Share Option Agreement, as amended, under the Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on March 1, 2021)

Employment Agreement, dated January 13, 2021, by and between the Company and Sherry Aulin (Filed With SEC on January 14, 2021)

Employment Agreement, dated January 13, 2021, by and between the Company and Simon Pimstone (Filed With SEC on January 14, 2021)

Amendment #1, dated January 13, 2021, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc (Filed With SEC on January 14, 2021)

Employment Agreement, dated January 13, 2021, by and between the Company and Ian Mortimer (Filed With SEC on January 14, 2021)

Employment Agreement, dated July 17, 2020, by and between the Company and Christopher Von Seggern (Filed With SEC on November 5, 2020)

At-the-Market Equity Offering Sales Agreement dated as of August 6, 2020, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on August 6, 2020)

Amendment to Asset Purchase Agreement, dated August 4, 2020, by and between the Company and 1st Order Pharmaceuticals, Inc (Filed With SEC on August 6, 2020)

Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder (Filed With SEC on June 3, 2020)

Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Robin Sherrington (Filed With SEC on March 9, 2020)

Amended and Restated Employment Agreement, dated March 20, 2019, by and between the Company and James Empfield (Filed With SEC on March 9, 2020)

Underwriting Agreement, dated January 22, 2020, among Xenon Pharmaceuticals Inc., Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC as... (Filed With SEC on January 23, 2020)

At-the-Market Equity Offering Sales Agreement dated as of November 5, 2019, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on November 5, 2019)

2019 Inducement Equity Incentive Plan and related form of share option agreement (Filed With SEC on September 10, 2019)

Form of Offer of Employment (CDN Executive) (Filed With SEC on March 25, 2019)

Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Ernesto Aycardi (Filed With SEC on March 25, 2019)

Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Ian Mortimer (Filed With SEC on March 25, 2019)

Form of Amended and Restated Employment Agreement (CDN Executive) (Filed With SEC on March 25, 2019)

Form of Offer of Employment (U.S. Executive) (Filed With SEC on March 25, 2019)

Form of Amended and Restated Employment Agreement (U.S. Executive) (Filed With SEC on March 25, 2019)

Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Simon Pimstone (Filed With SEC on March 25, 2019)

Xenon Pharmaceuticals Inc. (39)